- call +1-201-465-4211
- email sales@mrinsights.biz
Psoriasis is an autoimmune disease which is characterized by scaly patches of skin with inflammation and causes excessive production of new skin cells. Presently, there are no long term therapeutics available for the treatment of psoriasis. Chronic Plaque psoriasis is the one of the most common type of psoriasis. This disease condition is associated with several risk factors such as infection, psychological stress and others. Diagnosis of chronic plaque psoriasis is based on clinical appearance, is the case is severe then biopsy is recommended by the healthcare professionals in order to distinguish it from other conditions such as seborrheic dermatitis, ichen simplex chronicus and others.
Scope of the Report:
This report studies the Chronic Plaque Psoriasis Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Chronic Plaque Psoriasis Therapeutics market by product type and applications/end industries.
Increasing uptake of biological drugs is one of the major factor propelling the growth of the global chronic plaque psoriasis therapeutics market. Advances in inflammation and immunology research, introduction of innovative drugs and increased focus on the usage of combination therapies are further accentuating the demand for chronic plaque psoriasis drugs.
The global Chronic Plaque Psoriasis Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Chronic Plaque Psoriasis Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Abbvie
Novartis International
Pfizer
Merck
Astelllas Pharma
GlaxoSmithKline
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Clinical
Non-Clinical
Inactive
Market Segment by Applications, can be divided into
Hospitals
Ambulatory Surgical Centers
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Chronic Plaque Psoriasis Therapeutics Market Overview
1.1 Product Overview and Scope of Chronic Plaque Psoriasis Therapeutics
1.2 Classification of Chronic Plaque Psoriasis Therapeutics by Types
1.2.1 Global Chronic Plaque Psoriasis Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Chronic Plaque Psoriasis Therapeutics Revenue Market Share by Types in 2017
1.2.3 Clinical
1.2.4 Non-Clinical
1.2.5 Inactive
1.3 Global Chronic Plaque Psoriasis Therapeutics Market by Application
1.3.1 Global Chronic Plaque Psoriasis Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Others
1.4 Global Chronic Plaque Psoriasis Therapeutics Market by Regions
1.4.1 Global Chronic Plaque Psoriasis Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Chronic Plaque Psoriasis Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Chronic Plaque Psoriasis Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Chronic Plaque Psoriasis Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Chronic Plaque Psoriasis Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Chronic Plaque Psoriasis Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Chronic Plaque Psoriasis Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Abbvie
2.1.1 Business Overview
2.1.2 Chronic Plaque Psoriasis Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Abbvie Chronic Plaque Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis International
2.2.1 Business Overview
2.2.2 Chronic Plaque Psoriasis Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis International Chronic Plaque Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Pfizer
2.3.1 Business Overview
2.3.2 Chronic Plaque Psoriasis Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Pfizer Chronic Plaque Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck
2.4.1 Business Overview
2.4.2 Chronic Plaque Psoriasis Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck Chronic Plaque Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Astelllas Pharma
2.5.1 Business Overview
2.5.2 Chronic Plaque Psoriasis Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Astelllas Pharma Chronic Plaque Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 GlaxoSmithKline
2.6.1 Business Overview
2.6.2 Chronic Plaque Psoriasis Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 GlaxoSmithKline Chronic Plaque Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Chronic Plaque Psoriasis Therapeutics Market Competition, by Players
3.1 Global Chronic Plaque Psoriasis Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Chronic Plaque Psoriasis Therapeutics Players Market Share
3.2.2 Top 10 Chronic Plaque Psoriasis Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Chronic Plaque Psoriasis Therapeutics Market Size by Regions
4.1 Global Chronic Plaque Psoriasis Therapeutics Revenue and Market Share by Regions
4.2 North America Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Chronic Plaque Psoriasis Therapeutics Revenue by Countries
5.1 North America Chronic Plaque Psoriasis Therapeutics Revenue by Countries (2013-2018)
5.2 USA Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Chronic Plaque Psoriasis Therapeutics Revenue by Countries
6.1 Europe Chronic Plaque Psoriasis Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Chronic Plaque Psoriasis Therapeutics Revenue by Countries
7.1 Asia-Pacific Chronic Plaque Psoriasis Therapeutics Revenue by Countries (2013-2018)
7.2 China Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Chronic Plaque Psoriasis Therapeutics Revenue by Countries
8.1 South America Chronic Plaque Psoriasis Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Chronic Plaque Psoriasis Therapeutics by Countries
9.1 Middle East and Africa Chronic Plaque Psoriasis Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Chronic Plaque Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Chronic Plaque Psoriasis Therapeutics Market Segment by Type
10.1 Global Chronic Plaque Psoriasis Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Chronic Plaque Psoriasis Therapeutics Market Forecast by Type (2018-2023)
10.3 Clinical Revenue Growth Rate (2013-2023)
10.4 Non-Clinical Revenue Growth Rate (2013-2023)
10.5 Inactive Revenue Growth Rate (2013-2023)
11 Global Chronic Plaque Psoriasis Therapeutics Market Segment by Application
11.1 Global Chronic Plaque Psoriasis Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Chronic Plaque Psoriasis Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Ambulatory Surgical Centers Revenue Growth (2013-2018)
11.5 Others Revenue Growth (2013-2018)
12 Global Chronic Plaque Psoriasis Therapeutics Market Size Forecast (2018-2023)
12.1 Global Chronic Plaque Psoriasis Therapeutics Market Size Forecast (2018-2023)
12.2 Global Chronic Plaque Psoriasis Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Chronic Plaque Psoriasis Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Chronic Plaque Psoriasis Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Chronic Plaque Psoriasis Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Chronic Plaque Psoriasis Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Chronic Plaque Psoriasis Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Chronic Plaque Psoriasis Therapeutics Picture
Table Product Specifications of Chronic Plaque Psoriasis Therapeutics
Table Global Chronic Plaque Psoriasis Therapeutic
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
